Dendritic Cell Vaccination with Dengue Virus Adjuvant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer treatment face limitations due to self-identity of peptides, lack of immune activation, and tumor immune evasion mechanisms, leading to limited success in recognizing and destroying tumor cells.
Innovation Solution
Combining dendritic cell vaccination with the adjuvant effect of Dengue Virus Type 2 serotype strain DENV-2 #1710 to overcome tumor immune evasion and deplete tumor cells, using dendritic cells pulsed with tumor antigens and administering them after inducing a systemic infection to stimulate the immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell vaccination is used alone, then the immune system is targeted for cancer treatment, but the therapy fails due to self-identity of peptides and lack of immune activation
Solution Approach 1:
The patent combines dendritic cell vaccination with Dengue virus infection to create a synergistic immunotherapy approach. The Dengue virus serves as a potent adjuvant that activates the immune system while the dendritic cells present tumor antigens, overcoming the limitations of dendritic cell vaccination alone through the merging of two therapeutic modalities
Solution Approach 2:
The Dengue virus acts as an intermediary that bridges the gap between the dendritic cell vaccine and the immune system. By inducing a systemic infection, the virus activates immune pathways that enable the dendritic cells to effectively present tumor antigens and stimulate anti-tumor immunity, overcoming the self-identity problem
2Reliability
If tumor antigens are presented without immune activation, then antigen presentation occurs, but the immune system does not mount an effective response due to tumor immune evasion mechanisms
Solution Approach 1:
The patent applies preliminary action by inducing Dengue virus infection before administering the dendritic cell vaccine. This preliminary viral infection activates the immune system in advance, creating a primed state that enables effective tumor antigen recognition and response when the dendritic cells are subsequently administered
Solution Approach 2:
The combination of Dengue virus-induced immune activation with dendritic cell-mediated antigen presentation creates a synergistic effect that overcomes tumor immune evasion. The merged approach ensures both antigen presentation and immune system activation occur together, preventing evasion mechanisms from blocking the anti-tumor response
Data Source
AI summary
Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.